| Literature DB >> 32674214 |
Aline Bobato Lara Gongoria1, Denis Leonardo Fontes Jardim1,2, Diogo Assed Bastos1,3.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has rapidly spread all over the world in the past several months. No effective treatment for COVID-19 has been established. High transmissibility and considerable mortality rates have forced many national governments to implement quarantine measures. Many patients with cancer rely on clinical trials to receive their oncologic care, but the routine conduct of clinical trials has substantially changed because of the COVID-19 pandemic. The oncology research community should implement formal policies based on the guidance given from regulatory agencies, with the goal of minimizing the risks of COVID-19 infection while maintaining appropriate oncologic treatments for patients during this pandemic.Entities:
Mesh:
Year: 2020 PMID: 32674214
Source DB: PubMed Journal: Oncology (Williston Park) ISSN: 0890-9091 Impact factor: 2.990